Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,343.30

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,343.30 32

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Teva Pharmaceuticals USA, Inc. $524.98 8
US WorldMeds, LLC $333.24 10
Avanir Pharmaceuticals, Inc. $217.33 8
ACADIA Pharmaceuticals Inc $191.96 5
Eisai Inc. $75.79 1

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1659322691?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $1,343.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
US WorldMeds, LLC $63.1511/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501581 CMS
Teva Pharmaceuticals USA, Inc. $122.0811/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697869945 CMS
US WorldMeds, LLC $20.4411/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501583 CMS
Teva Pharmaceuticals USA, Inc. $115.8410/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697869943 CMS
Avanir Pharmaceuticals, Inc. $13.4010/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616587 CMS
Teva Pharmaceuticals USA, Inc. $14.6110/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697789935 CMS
Avanir Pharmaceuticals, Inc. $89.5309/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616777 CMS
Teva Pharmaceuticals USA, Inc. $119.6709/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697869939 CMS
Teva Pharmaceuticals USA, Inc. $21.2908/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697724977 CMS
US WorldMeds, LLC $15.9508/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501565 CMS
US WorldMeds, LLC $5.8307/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501563 CMS
ACADIA Pharmaceuticals Inc $172.4607/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699994609 CMS
Eisai Inc. $75.7907/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698080691 CMS
US WorldMeds, LLC $16.0006/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501551 CMS
Avanir Pharmaceuticals, Inc. $17.9706/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616781 CMS
US WorldMeds, LLC $16.0006/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501553 CMS
Avanir Pharmaceuticals, Inc. $24.2205/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616785 CMS
US WorldMeds, LLC $16.0005/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501549 CMS
US WorldMeds, LLC $102.3605/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501545 CMS
Avanir Pharmaceuticals, Inc. $19.3504/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616783 CMS
US WorldMeds, LLC $15.3304/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501547 CMS
Teva Pharmaceuticals USA, Inc. $13.7804/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697754473 CMS
Avanir Pharmaceuticals, Inc. $13.8403/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616779 CMS
Teva Pharmaceuticals USA, Inc. $106.8003/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697869941 CMS
ACADIA Pharmaceuticals Inc $0.8603/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699994605 CMS
ACADIA Pharmaceuticals Inc $1.0603/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699994607 CMS
ACADIA Pharmaceuticals Inc $0.6602/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699994601 CMS
ACADIA Pharmaceuticals Inc $16.9202/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699994603 CMS
Avanir Pharmaceuticals, Inc. $17.6102/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616775 CMS
US WorldMeds, LLC $62.1802/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699501517 CMS
Teva Pharmaceuticals USA, Inc. $10.9101/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697679047 CMS
Avanir Pharmaceuticals, Inc. $21.4101/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653616585 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

101 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $454.00 12/31/2023 Non-covered Recipient Entity
AMC RESEARCH
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimers Disease No dispute reported 06/30/2026 998413389
Principal investigator 1 ABBVIE INC. $74.50 12/31/2023 Non-covered Recipient Entity
AMC RESEARCH
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimers Disease No dispute reported 06/30/2026 998413391
Principal investigator 1 Novo Nordisk AS $5,698.44 12/18/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008022129
Principal investigator 1 Eisai Inc. $24,932.90 12/14/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935439
Principal investigator 1 Eisai Inc. $1,977.50 12/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443205
Principal investigator 1 Eisai Inc. $3,870.00 12/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443207
Principal investigator 1 Eisai Inc. $1,977.50 12/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443209
Principal investigator 1 Eisai Inc. $4,600.00 12/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443211
Principal investigator 1 Novo Nordisk AS $7.38 11/30/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008022085
Principal investigator 1 Novo Nordisk AS $4.89 11/30/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008022101
Principal investigator 1 Eisai Inc. $42,740.70 11/22/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935427
Principal investigator 1 Eisai Inc. $27,427.00 11/13/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443241
Principal investigator 1 Novo Nordisk AS $5.05 10/26/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397809
Principal investigator 1 Novo Nordisk AS $6.50 10/26/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008022071
Principal investigator 1 Novo Nordisk AS $5,108.76 10/23/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008022117
Principal investigator 1 Eisai Inc. $48,995.70 10/19/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443243
Principal investigator 1 Eisai Inc. $5,380.00 10/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443195
Principal investigator 1 Eisai Inc. $5,765.00 10/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443197
Principal investigator 1 Eisai Inc. $10,285.00 10/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443199
Principal investigator 1 Eisai Inc. $7,240.00 10/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443201
Principal investigator 1 Eisai Inc. $8,305.00 10/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443203
Principal investigator 1 Novo Nordisk AS $5.05 09/29/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397775
Principal investigator 1 Novo Nordisk AS $6.50 09/29/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397787
Principal investigator 1 Novo Nordisk AS $5,312.16 09/22/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397765
Principal investigator 1 Eisai Inc. $54,783.90 09/21/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443185
Principal investigator 1 Novo Nordisk AS $6.26 09/12/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397797
Principal investigator 1 Eisai Inc. $2,800.00 09/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443187
Principal investigator 1 Eisai Inc. $3,430.00 09/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443189
Principal investigator 1 Eisai Inc. $1,922.50 09/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443191
Principal investigator 1 Eisai Inc. $1,922.50 09/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443193
Principal investigator 1 Eisai Inc. $38,289.60 08/18/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443183
Principal investigator 1 Novo Nordisk AS $779.76 08/18/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397755
Principal investigator 1 Eisai Inc. $13,839.00 08/07/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443179
Principal investigator 1 Novo Nordisk AS $11,010.60 07/26/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397743
Principal investigator 1 Eisai Inc. $36,941.40 07/24/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443181
Principal investigator 1 Eisai Inc. $13,550.00 07/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443235
Principal investigator 1 Eisai Inc. $10,475.00 07/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443237
Principal investigator 1 Eisai Inc. $25,115.00 07/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443239
Principal investigator 1 Novo Nordisk AS $3,083.40 06/23/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007397733
Principal investigator 1 Novo Nordisk AS $6.30 06/19/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101393
Principal investigator 1 Novo Nordisk AS $7.95 06/19/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101405
Principal investigator 1 Genentech, Inc. $12,402.00 06/15/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229359
Principal investigator 1 Genentech, Inc. $19,198.00 06/13/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229207
Principal investigator 1 Genentech, Inc. $7,458.00 06/13/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229243
Principal investigator 1 Genentech, Inc. $19,206.00 06/13/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229255
Principal investigator 1 Genentech, Inc. $250.00 06/13/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Gantenerumab Open Label Extension No dispute reported 06/30/2026 1040229335
Principal investigator 1 Genentech, Inc. $6,192.00 06/13/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229371
Principal investigator 1 Genentech, Inc. $1,500.00 06/12/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Gantenerumab Open Label Extension No dispute reported 06/30/2026 1040229183
Principal investigator 1 Genentech, Inc. $50,319.00 06/12/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Gantenerumab in Early AD No dispute reported 06/30/2026 1040229195
Principal investigator 1 Genentech, Inc. $17,075.00 06/12/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Gantenerumab in Early AD No dispute reported 06/30/2026 1040229347
Principal investigator 1 Genentech, Inc. $1,770.00 06/06/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229301
Principal investigator 1 Novo Nordisk AS $5.05 06/06/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101361
Principal investigator 1 Novo Nordisk AS $6.50 06/06/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101375
Principal investigator 1 Novo Nordisk AS $41.26 06/02/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767805
Principal investigator 1 Novo Nordisk AS $5.05 06/01/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101419
Principal investigator 1 Novo Nordisk AS $6.50 06/01/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101433
Principal investigator 1 Novo Nordisk AS $3,024.00 05/26/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101467
Principal investigator 1 Eisai Inc. $46,315.80 05/19/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443177
Principal investigator 1 Eli Lilly and Company $554.00 05/10/2023 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US No dispute reported 06/30/2026 1038069213
Principal investigator 1 Eisai Inc. $26,948.70 05/08/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443175
Principal investigator 1 Eisai Inc. $4,465.00 05/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443229
Principal investigator 1 Eisai Inc. $11,510.00 05/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443231
Principal investigator 1 Eisai Inc. $2,580.00 05/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443233
Recipient Eli Lilly and Company $150.00 04/28/2023 Covered Recipient Physician A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038053855
Principal investigator 1 Novo Nordisk AS $34,876.08 04/26/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1008101451
Principal investigator 1 Eisai Inc. $9,644.85 04/17/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443163
Principal investigator 1 Genentech, Inc. $590.00 04/12/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229267
Principal investigator 1 Eisai Inc. $47,467.80 04/05/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443173
Principal investigator 1 Eisai Inc. $2,580.00 04/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443225
Principal investigator 1 Eisai Inc. $5,725.00 04/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443227
Principal investigator 1 Genentech, Inc. $1,880.00 03/27/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Gantenerumab Open Label Extension No dispute reported 06/30/2026 1040229219
Principal investigator 1 Novo Nordisk AS $674.64 03/24/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767799
Principal investigator 1 ABBVIE INC. $3,000.00 03/22/2023 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease No dispute reported 06/30/2026 998375473
Principal investigator 1 Eisai Inc. $35,029.00 03/20/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443161
Principal investigator 1 Eli Lilly and Company $2,008.09 03/20/2023 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038086209
Principal investigator 1 Eisai Inc. $4,090.00 03/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443221
Principal investigator 1 Eisai Inc. $4,005.00 03/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443223
Principal investigator 1 Genentech, Inc. $18,819.00 02/27/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229323
Principal investigator 1 Novo Nordisk AS $1,500.00 02/24/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767785
Principal investigator 1 Novo Nordisk AS $1,058.40 02/24/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767791
Principal investigator 1 Eisai Inc. $64,927.20 02/20/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443171
Principal investigator 1 Genentech, Inc. $4,716.00 02/10/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Gantenerumab Open Label Extension No dispute reported 06/30/2026 1040229383
Principal investigator 1 Eisai Inc. $8,120.00 02/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443215
Principal investigator 1 Eisai Inc. $7,060.00 02/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443217
Principal investigator 1 Eisai Inc. $11,125.00 02/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443219
Principal investigator 1 Eli Lilly and Company $2,962.90 01/26/2023 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038067205
Principal investigator 1 Eli Lilly and Company $11,958.53 01/26/2023 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038069207
Principal investigator 1 Novo Nordisk AS $7,513.38 01/25/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767779
Principal investigator 1 Eisai Inc. $15,774.30 01/20/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443169
Principal investigator 1 Novo Nordisk AS $22.41 01/16/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767767
Principal investigator 1 Novo Nordisk AS $10.39 01/16/2023 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1007767773
Principal investigator 1 Biogen, Inc. $544,423.00 01/12/2023 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1012173103
Principal investigator 1 Biogen, Inc. $104,999.00 01/06/2023 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1012176215
Principal investigator 1 Eisai Inc. $179,407.60 01/06/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443165
Principal investigator 1 Eisai Inc. $82,719.90 01/06/2023 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025443167
Principal investigator 1 Genentech, Inc. $740.00 01/06/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Prevention Study No dispute reported 06/30/2026 1040229277
Principal investigator 1 Genentech, Inc. $65.00 01/04/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229231
Principal investigator 1 Genentech, Inc. $65.00 01/04/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PostGraduate Roll Over Study No dispute reported 06/30/2026 1040229289
Principal investigator 1 Genentech, Inc. $8,950.00 01/04/2023 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Prevention Study No dispute reported 06/30/2026 1040229313
Principal investigator 1 Eli Lilly and Company $1,267,248.15 01/03/2023 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038069727
Principal investigator 1 Eisai Inc. $11,585.00 01/01/2023 Non-covered Recipient Entity
AMC Research LLC
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025443213